TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2539180
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir and oral acyclovir
Study: 773085
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lozenges
Study: 28120017
Drug: Distal sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal sciatic nerve block (DSB) out-of-plane with 30 ml of Mepivacaine 1%
Study: 28120017
Drug: Proximal sciatic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal sciatic nerve block (DSB) in-plane with 30 ml of Mepivacaine 1%
Study: 11414530
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol via Jet nebulizer
Study: 11414530
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol via MDI-spacer
Study: 2443539
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg prednisone per day for 2 days before challenge
Study: 29696921
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with fluoxetine
Study: 29696921
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture combined with fluoxetine
Study: 27706466
Drug: Conservative oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative oxygen therapy (maintaining Pao2 between 70 and 100 mm Hg or Spo2 between 94% and 98%)
Study: 27706466
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy (allowing Pao2 values up to 150 mm Hg or Spo2 between 97% and 100%)
Study: 1538721
Drug: Continuous medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous medical therapy (lifestyle modifications and up to four medications)
Study: 1538721
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for symptoms only
Study: 1538721
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (Nissen fundoplication)
Study: 24419307
Drug: EVP-6124 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 0.3 mg (n=8)
Study: 24419307
Drug: EVP-6124 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 1.0 mg (n=9)
Study: 24419307
Drug: EVP-6124 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVP-6124 (0.3 mg and 1.0 mg)
Study: 12405434
Drug: Early interventional
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early interventional therapy
Study: 10091789
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2) followed by IL-2 (18 x 10(6) IU/m2) on Days 3-6 and Days 17-21 (Arm 1)
Study: 10091789
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and IL-2 with subcutaneous IFN (9 x 10(6) U, 3 times a week during IL-2 administration) (Arm 2)
Study: 8573537
Drug: Weekly dose-intensive
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dose-intensive chemotherapy
Study: 8573537
Drug: 3-weekly conventional
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-weekly conventional chemotherapy
Study: 465271
Drug: Droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.5 mg with Diazepam 5 mg
Study: 465271
Drug: Larger doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger doses of droperidol with diazepam
Study: 465271
Drug: Larger doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger doses of diazepam with droperidol
Study: 21266516
Drug: Irinotecan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 50 mg/m2 on days 1, 8, and 15 combined with carboplatin AUC 5 mg x min/ml
Study: 21266516
Drug: Etoposide 140
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 140 mg/m2 on days 1-3 combined with carboplatin AUC 5 mg x min/ml
Study: 15500532
Drug: Acupressure at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure at Sanyinjiao point (self-treatment follow-up)
Study: 9630110
Drug: Ibutilide low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide low dose (0.005 mg/kg + 0.001 mg/kg)
Study: 9630110
Drug: Ibutilide middle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide middle dose (0.01 mg/kg + 0.002 mg/kg)
Study: 9630110
Drug: Ibutilide high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide high dose (0.02 mg/kg + 0.004 mg/kg)
Study: 10421596
Drug: Ibutilide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (all doses)
Study: 7526774
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of oral corticosteroids
Study: 2464722
Drug: Conventional topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional topical hemostatic agent
Study: 29043998
Drug: Antiglaucoma medication
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiglaucoma medication (drug group)
Study: 22850760
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg orally with water
Study: 16885723
Drug: Liquid hemp
Normalized name: hemp
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid hemp oil (0.39 and 14.8 mg THC/d)
Study: 16885723
Drug: Hemp oil
Normalized name: HEMP OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp oil in capsules (0.47 mg THC/d)
Study: 16885723
Drug: Dronabinol capsules
Normalized name: Dronabinol Capsules
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol capsules (7.5 mg THC/d)
Study: 9357876
Drug: 0.09 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09 mg/kg morphine
Study: 9357876
Drug: 0.09 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09 mg/kg morphine plus 0.3 mg/kg methylnaltrexone
Study: 1376847
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg twice daily for 3 months
Study: 4007415
Drug: Adenine arabinoside
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenine arabinoside (Ara‐A) alone (10 mg/kg body wt for 4‐8 weeks)
Study: 4007415
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (prednisolone 40 mg/day for 4 weeks followed by Ara‐A)
Study: 27611806
Drug: Propofol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (20 mg IV)
Study: 26990304
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg IV)
Study: 23855406
Drug: Standard prenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prenatal plus brief cognitive behavioural therapy (CBT) initiated between the 20th and 28th gestation week
Study: 22449251
Drug: Adefovir and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir and lamivudine (100 mg/daily)
Study: 22449251
Drug: Adefovir alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir alone (10 mg/daily)
Study: 18698234
Drug: Levodopa treatment
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa treatment in PD patients
Study: 11773285
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy offered to women whose tumors express hormone receptor protein
Study: 11438563
Drug: Anthracyclines in
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracyclines in adjuvant chemotherapy regimens
Study: 11438563
Drug: Adjuvant dose-intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant dose-intensive chemotherapy regimens
Study: 8167785
Drug: Hydration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration treatment
Study: 25997653
Drug: 40 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg/day of docosahexaenoic acid (DHA)
Study: 25997653
Drug: 80 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg/day of docosahexaenoic acid (DHA)
Study: 25997653
Drug: 120 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/kg/day of docosahexaenoic acid (DHA)
Study: 23193009
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (1-4 capsules daily containing 277.8 mg DHA and 39.0 mg EPA)
Study: 19347696
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) adaptation of the Coping with Stress program, duration not specified.
Study: 7554633
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg twice daily
Study: 10910900
Drug: Flt3 ligand
Normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flt3 ligand (FL) administration
Study: 9308064
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg.kg‐1
Study: 8467623
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (400 mg orally with food twice a day)
Study: 8467623
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg orally, fasting, three times a day)
Study: 9088820
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments together
Study: 16467022
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg daily (standard regimen)
Study: 16467022
Drug: Intermittent terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent terbinafine 350 mg daily for 2 weeks on, 2 weeks off
Study: 15221928
Drug: Early therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early therapeutic lymphadenectomy and adjuvant interferon alfa‐2b therapy
Study: 11534891
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of formoterol
Study: 11534891
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of formoterol
Study: 8422839
Drug: Three-injection regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-injection regimen (regular prebreakfast, regular prelunch, and [regular+ultralente] predinner)
Study: 8422839
Drug: Two-injection regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-injection regimen ([regular+intermediary] prebreakfast and predinner)
Study: 8422839
Drug: Three-injection regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-injection regimen
Study: 8422839
Drug: Three-injection regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-injection regimen and Two-injection regimen
Study: 18520178
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with cedar pollen extract
Study: 18520178
Drug: Cypress pollen
Normalized name: Cypress pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cypress pollen specific IgE antibodies
Study: 14504627
Drug: High group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High group (individual face-to-face counselling up to 1 hour monthly for 1 year)
Study: 14504627
Drug: Low group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low group (one face-to-face individual counselling session, then monthly telephone contacts for 1 year)
Study: 8899756
Drug: Heparinized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized saline flush (2.5 ml, 100 U/ml)
Study: 8899756
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline flush (5 ml)
Study: 6846212
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal insulin responses)
Study: 30540689
Drug: Control (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intravenous thrombolysis with urokinase)
Study: 30184455
Drug: Baloxavir (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baloxavir (40 or 80 mg)
Study: 24999213
Drug: Buscopan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan (20 mg intravenously)
Study: 22173517
Drug: Selective digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective digestive decontamination (SDD) with oral gentamicin (80 mg 4 times per day) and oral polymyxin E gel (0.5 g 4 times per day) for 7 days
Study: 22173517
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo gel and 2 placebo oral solutions 4 times per day for 7 days)
Study: 10352387
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + transdermal estrogen
Study: 8687263
Drug: Computer reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer reminders printed on daily rounds reports about preventive care for which their patients were eligible.
Study: 28393258
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen treatment (usual care)
Study: 25418079
Drug: Biotène(®) mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotène(®) mouthwash Oral Rinse
Study: 25117615
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 250 mg
Study: 25117615
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 500 mg
Study: 22526411
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 750 mg
Study: 22526411
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 1000 mg
Study: 11787914
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Study: 11787914
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Study: 9422305
Drug: Ketoprofen 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 1.4 mg x kg(‐1)
Study: 9422305
Drug: Ketorolac 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.4 mg x kg(‐1)
Study: 9422305
Drug: Diclofenac 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1.1 mg x kg(‐1)
Study: 25751000
Drug: Collaborative &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative & Proactive Solutions (CPS)
Study: 31376090
Drug: Rivaroxaban and
Normalized name: rivaroxaban and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban and Warfarin
Study: 20544158
Drug: Sham intramuscular
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham intramuscular dry needle puncture (Control)
Study: 18793221
Drug: Hemofiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemofiltration with constant flow of 300 mL/m²/min and filtrate volume of 3000 mL
Study: 12787969
Drug: CEE (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (conjugated equine estrogens 0.625 mg)
Study: 16680067
Drug: CEE/MPA (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg)
Study: 12787969
Drug: E(2)/NETA (17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2)/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Study: 12787969
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (women who declined or did not qualify for treatment)
Study: 10951147
Drug: Cyclosporin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (4 mg kg‐1 daily for 4 weeks)
Study: 8838437
Drug: Sustained-release tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tramadol (100 mg)
Study: 8838437
Drug: Sustained-release tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tramadol (200 mg)
Study: 8838437
Drug: Sustained-release tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tramadol (100 mg and 200 mg)
Study: 8838437
Drug: Sustained-release tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tramadol
Study: 1468244
Drug: CR dihydrocodeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR dihydrocodeine (60 mg) tablets (1 tablet twice daily to 2 tablets daily)
Study: 1468244
Drug: Combination dextropropoxyphene
Normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination dextropropoxyphene (32.5 mg)/paracetamol (325 mg) tablets (2 tablets 3‐times daily to 2 tablets 4‐times daily)
Study: 28012819
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR (6 μg)
Study: 28012819
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR (10 μg)
Study: 28012819
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR (15 μg)
Study: 28012819
Drug: Bimatoprost SR
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost SR (20 μg)
Study: 28012819
Drug: Topical bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bimatoprost 0.03%
Study: 28012819
Drug: Topical bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bimatoprost
Study: 26497960
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) exposure for 2 hours with a particulate matter concentration of 300 μg/m(3)
Study: 19528562
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice, 1800 mg twice daily for 24 weeks
Study: 19528562
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 24 weeks
Study: 17530404
Drug: Random Controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random Controlled Trial (RCT) design for evaluating sexual offender treatment
Study: 17530404
Drug: Alternative strategies
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative strategies for evaluating treatment
Study: 17151968
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution (500 ml of 30% dextrose solution, containing 100 IU insulin and 80 mEq of potassium, at a rate of 1 ml x kg (‐1) x h (‐1))
Study: 14615106
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis extract (n=211)
Study: 22427020
Drug: Caffeine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1 mg/kg)
Study: 30643069
Drug: Manipulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation therapy
Study: 19018915
Drug: TTT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TTT intervention (educational train-the-trainer course plus pharmacotherapy feedback)
Study: 15675981
Drug: rHuEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO therapy
Study: 8602180
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of beta carotene per day and 25,000 IU of retinol (vitamin A) per day
Study: 1943090
Drug: rHGH (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHGH (0.2 mg/kg.d)
Study: 30702971
Drug: Celecoxib with
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib with neoadjuvant chemotherapy
Study: 30702971
Drug: Celecoxib with
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib with neoadjuvant chemotherapy in PTGS2-low group (n = 100)
Study: 28476567
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily insulin dose per kilogram
Study: 23645323
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (34% of children)
Study: 3090583
Drug: O +
Normalized name: Acti-Lipo + Pyridoxine Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: O + O (no drugs)